TARRYTOWN, N.Y. – Regeneron (NASDAQ:) Prescribed drugs, Inc. (NASDAQ:REGN) reported third-quarter 2024 outcomes that exceeded analyst expectations, with income progress pushed by robust efficiency throughout its product portfolio.
The biotechnology firm posted adjusted earnings per share of $12.46, surpassing the analyst consensus of $11.72. Income for the quarter rose 11% year-over-year to $3.72 billion, beating estimates of $3.66 billion.
Dupixent, Regeneron’s blockbuster drug developed with Sanofi (NASDAQ:), noticed world internet gross sales improve 23% to $3.82 billion in comparison with the identical quarter final 12 months. The corporate’s eye illness franchise, together with EYLEA HD and EYLEA, grew U.S. internet gross sales by 3% to $1.54 billion, with EYLEA HD contributing $392 million. Libtayo, Regeneron’s most cancers immunotherapy, posted a 24% improve in world internet gross sales to $289 million.
“Regeneron had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,” mentioned Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Govt Officer of Regeneron.
The corporate highlighted latest regulatory approvals, together with Dupixent’s FDA approval for persistent obstructive pulmonary illness (COPD) with an eosinophilic phenotype, marking the primary biologic remedy for this indication within the U.S.
Regeneron continues to put money into its analysis and improvement pipeline, with roughly 40 product candidates in varied phases of improvement. The corporate expects knowledge from a number of pivotal research within the coming months, spanning indications reminiscent of non-small cell lung most cancers, thrombosis, and weight problems.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
